Clinical trials: Hemophilia a
Hemophilia
The Effectiveness of Recombinant Coagulation Factor IX With Recombinant Albumin (rIX-FP) in Severe Hemophilia B Patients
The pivotal clinical data support prolonged dosing intervals of up to 14 days for routine prophylaxis in hemophilia B patients. The majority of adult and pediatric patients using Idelvion for routine prophylaxis had a median…
- Trial name
- NCT04108260
- Testing
- Albutrepenonacog Alfa 1 UNT [IDELVION]
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- National Taiwan University Hospital
Hemophilia A, Hemophilia B
Virtual Reality for Hemophilia
Children with hemophilia are exposed to intravenous (IV) procedures that cause pain/anxiety and distraction methods can be employed to improve the patient experience.
- Trial name
- NCT03507582
- Testing
- Virtual Reality Distraction, Standard of Care Distraction
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Nationwide Children's Hospital
Hemophilia A
Safety,Efficacy and Pharmacokinetics Evaluation of SCT800 in Previously Treated Paediatric Patients With Severe Haemophilia A.
This study is a multicenter phase III uncontrolled open-label trial to evaluate the efficacy,safety and pharmacokinetics of SCT800 in regular prophylaxis and perioperative treatment in patients (<12 years old) with severe…
- Trial name
- NCT03947320
- Testing
- Recombinant Human Coagulation FVIII
- Volunteers
- 70 people
- Sponsor
- Sinocelltech Ltd.
Hemophilia
Isokinetic Strength Training On Functional Performance
Hemophilia is a congenital , recessive clotting disease featured by cerebra ( The most dangerous ) and musculoskeletal (the most common and disabling) hemorrhages .
- Trial name
- Isokinetic (NCT07035080)
- Testing
- interferential therapy, tradional physical therapy
- Volunteers
- 30 people
- Sponsor
- Kafrelsheikh University
Congenital Hemophilia A
Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A
This is an international, multicenter, open-label study to assess the efficacy, safety, and pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe hemophilia A.
- Trial name
- NCT02093897
- Testing
- rVIII-SingleChain
- Where
- 37 sites in United States, Australia and 17 more
- Volunteers
- 84 people
- Sponsor
- CSL Behring
Haemophilia
Effectiveness of Psychological Interventions in Haemophilia
The purpose of this study is to evaluate the relative effectiveness of two psychological interventions, cognitive-behavioral therapy (CBT) and hypnosis (Hyp), in preventing and managing pain, regulating emotional state and…
- Trial name
- PSY_HaEMOPEQ (NCT02870452)
- Testing
- Hypnosis, Cognitive-Behavioral Therapy
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- University of Minho
Hemophilia A, Hemophilia B
Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE or RIXUBIS
This 6-month prospective outcomes study addresses the association between timing of infusion, patient activity levels, and bleeding episodes through patient-reported measurements.
- Trial name
- SPACE (NCT02190149)
- Testing
- ADVATE (Antihemophilic Factor [Recombinant]), RIXUBIS (Coagulation Factor IX [Recombinant])
- Where
- 17 sites in United States
- Volunteers
- 64 people
- Sponsor
- Baxalta now part of Shire
Hemophilia A
Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants
This multicenter, open-label, Phase 3 study with randomized and non-randomized arms is designed to investigate the efficacy, safety, and pharmacokinetics of emicizumab in participants with hemophilia A regardless of factor VIII…
- Trial name
- HAVEN 5 (NCT03315455)
- Testing
- Emicizumab
- Where
- 13 sites in China, Hong Kong and 2 more
- Volunteers
- 85 people
- Sponsor
- Hoffmann-La Roche
Hemophilia A, Hemophilia B
Ultrasonography in Hemophilic Joint Disease and Serum Markers
Hemophilia is a bleeding disorder (deficiency of a blood clotting factor/ protein) resulting in bleeding in joints and muscles. As patients continue to bleed into their joints they develop progressive joint damage leading to…
- Conditions
- Hemophilia A, Hemophilia B, Hemarthroses
- Trial name
- NCT02634918
- Testing
- ultrasound
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Von Willebrand Diseases, Hemophilia A
BT200 in Hereditary Bleeding Disorders
BT200 is a PEGylated aptamer that binds to the A1 domain of human von Willebrand factor (VWF). At low doses, BT200 blocks the clearance of VWF antigen (VWF Ag) from the circulation and causes an increase in concentrations of both…
- Trial name
- NCT04677803
- Testing
- BT200
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Medical University of Vienna
Congenital Bleeding Disorder, Haemophilia A
Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A.
This trial is conducted globally. The aim of this trial is to evaluate the haemostatic effect of NNC 0129-0000-1003 during surgical procedures in subjects with haemophilia A.
- Trial name
- pathfinder™3 (NCT01489111)
- Testing
- turoctocog alfa pegol
- Where
- 70 sites in United States, Australia and 19 more
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Hemophilia A
An Open Label Study to Determine the Safety and Efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection in Adolescent and Adult Patients With Hemophilia A.
The primary objectives of the study are to evaluate the efficacy of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection (FRSW107) in the Prevention and Treatment of Bleeding in patients with hemophilia A.
- Trial name
- NCT04456387
- Testing
- Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection
- Where
- 17 sites in China
- Volunteers
- 119 people
- Sponsor
- Zhengzhou Gensciences Inc
Hemophilia A or B With Inhibitor
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors
The purpose of this multicentre, randomized, double-blinded, single dose, two-way cross-over study, is to compare the pharmacokinetics (PK) and pharmacodynamic (PD) of two different doses of the biosimilar eptacog alfa…
- Trial name
- NCT03935334
- Testing
- Biosimilar eptacog alfa, activated (AryoSeven), Eptacog alfa, activated (Novoseven)
- Where
- 8 sites in Iran, Turkey (Türkiye)
- Volunteers
- 48 people
- Sponsor
- AryoGen Pharmed Co.
Hemophilic Arthropathy, Chronic Pain
Multicomponent Pain Self-Management in Adults With Haemophilic Arthropathy
Background: Haemophilic arthropathy is associated with chronic pain, functional limitation and impaired quality of life. Pain interference may also be influenced by cognitive, emotional and behavioural factors.
- Conditions
- Hemophilic Arthropathy, Chronic Pain, Hemophilia A, Hemophilia B
- Trial name
- NCT07860632
- Testing
- Multicomponent pain self-management programme
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Investigación en Hemofilia y Fisioterapia
Hemophilia A
Acquired Hemophilia A and Autoimmunity. Study of Lymphocyte Populations and Myeloid-Derived Suppressor Cells
Acquired hemophilia A is a rare condition of hemostasis secondary to the development of antibodies against factor VIII. This is a potentially serious pathology that can be life-threatening due to the major risk of bleeding caused…
- Trial name
- IMMUNHEMAC (NCT04805021)
- Testing
- no intervention
- Where
- 2 sites in France
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Nantes University Hospital
Hemophilia A
Evaluation of Clot Stability Induced by Solulin: Evaluation of New Solulin Mutants Lacking Protein C Activation Capacity
Hemophilia A is a rare X chromosome-linked recessive bleeding disorder that concerns one individual in 5000. In its severe form, hemophilia A is a life-threatening, crippling hemorrhagic disease.
- Trial name
- SOLUCLOT (NCT02911233)
- Testing
- Thromboelastograpgy
- Where
- France
- Volunteers
- 10 people
- Sponsor
- University Hospital, Caen
Hemophilia a, Hemophilia B
The Long-term Safety and Efficacy of SerpinPC in Subjects with Hemophilia Who Completed a Sponsored SerpinPC Clinical Trial
The purpose of the study is to evaluate the efficacy, safety, tolerability and pharmacokinetic (PK) profile of prophylactic SerpinPC in participants with hemophilia
- Conditions
- Hemophilia a, Hemophilia B, Hemophilia a with Inhibitor, Hemophilia B with Inhibitor
- Trial name
- PRESent-6 (NCT06568302)
- Testing
- SerpinPC
- Where
- 2 sites in Georgia, Moldova
- Volunteers
- 15 people
- Sponsor
- ApcinteX Ltd
Hemophilia
Musculoskeletal Function in Hemophilia
Hemophilia, which results from deficiency of factor VIII or IX, is a common hereditary X-linked bleeding disorder affecting up to 10/100,000 population. About 60-70% of them have severe disease (factor level <1%).
- Trial name
- NCT00324493
- Where
- 10 sites in Argentina, Brazil and 7 more
- Volunteers
- 250 people
- Sponsor
- Christian Medical College, Vellore, India
Hemophilia A Without Inhibitor
The Effects of Virtual Reality-Based Gamified Rehabilitation in Children With Hemophilia
Hemophilia is an inherited bleeding disorder caused by deficiencies or low levels of clotting factors VIII (hemophilia A) and IX (hemophilia B).
- Trial name
- NCT07200609
- Testing
- Virtual Reality Intervention, Home-Based Exercise Intervention
- Volunteers
- 20 people
- Sponsor
- Hacettepe University
Hemophilia A
Long-term Anticoagulation in a Patient With Severe Hemophilia A
To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII)…
- Trial name
- HAAC (NCT07314983)
- Where
- France
- Volunteers
- 1 people
- Sponsor
- University Hospital, Strasbourg, France